دبئی میں گیسٹرواینٹرولوجسٹ — ہاضمے کی صحت کے ماہر

Helicobacter pylori (H. pylori) is a bacterium that infects the stomach lining of approximately half the global population. In the Middle East and South Asia, prevalence rates can exceed 70 percent. While many carriers remain asymptomatic, H. pylori is the primary cause of gastritis, peptic ulcers, and a significant risk factor for gastric cancer. Diagnosis is straightforward using the urea breath test, stool antigen testing, or serology. Treatment involves a combination of antibiotics and acid-suppressing medication, typically for 14 days, followed by confirmation of eradication four to six weeks later. Rising antibiotic resistance makes proper testing, guided therapy selection, and confirmed clearance essential components of modern H. pylori management.

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver condition globally, with the UAE and Gulf region reporting some of the highest prevalence rates due to high rates of obesity, diabetes, and metabolic syndrome. NAFLD represents a spectrum from simple fat accumulation in the liver (steatosis) to non-alcoholic steatohepatitis (NASH), which involves inflammation and cellular damage that can progress to fibrosis, cirrhosis, and liver failure. Early detection through liver function blood tests, ultrasound imaging, and non-invasive fibrosis scoring is critical because NAFLD in its early stages is fully reversible with lifestyle changes. A Mediterranean-style diet, regular aerobic and resistance exercise, gradual weight loss, and management of metabolic risk factors form the cornerstone of treatment. Our integrated approach at DCDC addresses fatty liver within the broader context of metabolic health, coordinating with endocrinologists and cardiologists when needed.